Comparative Pharmacology
Head-to-head clinical analysis: HYDRALAZINE versus MINOXIDIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRALAZINE versus MINOXIDIL.
Hydralazine vs MINOXIDIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydralazine is a direct-acting vasodilator that relaxes arteriolar smooth muscle, leading to decreased peripheral vascular resistance and blood pressure. Its exact mechanism is unclear but may involve interference with calcium movement and increased cGMP levels.
Minoxidil is a potassium channel opener that hyperpolarizes vascular smooth muscle cells, leading to vasodilation. In hair follicles, it promotes hair growth by increasing blood flow and prolonging the anagen phase, possibly through stimulation of prostaglandin synthesis.
10-50 mg orally every 6 hours, titrate to maximum 300 mg/day; 10-20 mg intramuscularly or intravenously every 4-6 hours as needed.
Oral: 5-40 mg/day in 1-2 divided doses, starting at 5 mg/day and titrating upward; Topical: 1 mL of 2% or 5% solution twice daily.
MODERATE Risk
MODERATE Risk
Clinical Note
moderateMinoxidil + Etacrynic acid
"The risk or severity of adverse effects can be increased when Minoxidil is combined with Etacrynic acid."
Clinical Note
moderateMinoxidil + Furosemide
"The risk or severity of adverse effects can be increased when Minoxidil is combined with Furosemide."
Clinical Note
moderateMinoxidil + Bumetanide
"The risk or severity of adverse effects can be increased when Minoxidil is combined with Bumetanide."
Clinical Note
moderateHydralazine + Benzydamine
The terminal elimination half-life of hydralazine is approximately 2-4 hours in patients with normal renal function. However, the duration of antihypertensive effect may be longer (6-12 hours) due to tissue binding and slow release from vascular smooth muscle. In renal impairment, half-life may extend to 7-16 hours, necessitating dose adjustment.
Terminal elimination half-life: 4.2 hours; clinical context: may be prolonged in renal impairment (up to 18 hours), requiring dose adjustment.
Hydralazine is primarily metabolized in the liver via N-acetylation and hydroxylation. Approximately 80-90% of the drug is eliminated in urine as metabolites, with less than 10% excreted unchanged. A small fraction appears in feces via biliary excretion.
Renal: 90% as unchanged drug and metabolites; fecal: 10% via bile.
Category A/B
Category A/B
Vasodilator
Vasodilator / Hair Growth Stimulant
"Hydralazine may decrease the antihypertensive activities of Benzydamine."